Consequently, prospective clinical trials are required to assess the specificity of [18F]FSPG for NRF2 in humans and to determine the thresholds of [18F]FSPG retention to classify tumours into NRF2-high or NRF2-low. Here, NFE2L2 is linked to neoplasm.